On June 19th, Gelon's announcement revealed that Kaisheng New Materials (301069.SZ) recently received notice from its controlling shareholder, Huapont Life Sciences, that it sold a total of 1,000,000 convertible bonds of Kaisheng New Materials through block trading from June 11, 2024, to June 18, 2024, which accounted for 15.38% of the total issued.

According to the approval letter "China Securities Regulatory Commission's Approval for Shandong Kaisheng New Materials Co., Ltd. to register for the issuance of convertible corporate bonds to unspecified objects" (CSRC Approval [2023] No. 1893), Kaisheng New Materials Co., Ltd. (hereinafter referred to as the "Company") is allowed to issue 6.5 million convertible corporate bonds to unspecified objects. The face value of each bond is RMB100.00, and the total amount of funds raised is RMB650.00 million. With the approval of the Shenzhen Stock Exchange, the convertible corporate bonds issued by the company to unspecified objects will start trading on the Shenzhen Stock Exchange on December 15, 2023, with the bond code "123233" and the bond shorthand "Kaisheng Convertible Bond". In this issuance of convertible bonds, the controlling shareholder of the company, Huapont Life Sciences, was allocated a total of 2,892,862 convertible bonds, which accounted for 44.51% of the total convertible bonds issued in this round.